<DOC>
	<DOCNO>NCT00168766</DOCNO>
	<brief_summary>The primary objective study determine whether combination treatment ( add methylprednisolone Avonex ) reduce progression disability 4 year compare Avonex alone . The study also investigate whether combination therapy impact incidence relapse brain atrophy measure MRI .</brief_summary>
	<brief_title>Avonex ( Interferon-beta-1a ) Avonex Plus Methylprednisolone Treatment Relapsing-remitting MS</brief_title>
	<detailed_description>Approximately 340 therapy-naïve MS patient relapsing-remitting form disease randomize receive Avonex alone Avonex plus methylprednisolone ( MP ) . Patients receive MP 500 mg po 3 day every month match placebo . The patient follow 3-monthly basis 4 year disability primary parameter efficacy time .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Informed consent Relapsing remit MS accord Poser criterion McDonell criterion naïve therapy Disability EDSS score 4.0 less baseline Clinical activity define least one relapse last year Relapse month prior enrolment Treatment immunosuppressive drug MS History major depression Former severe reaction corticosteroid Pregnant woman Diabetes mellitus , drug alcohol dependency Known suspect allergy trial product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Combination therapy multiple sclerosis</keyword>
</DOC>